2/24
04:59 am
olma
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit [Yahoo! Finance]
Low
Report
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit [Yahoo! Finance]
2/19
04:30 pm
olma
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
2/16
12:38 pm
olma
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating [Yahoo! Finance]
Low
Report
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating [Yahoo! Finance]
2/14
01:08 pm
olma
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit [Yahoo! Finance]
Low
Report
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit [Yahoo! Finance]
2/11
08:00 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.
2/4
04:30 pm
olma
Olema Oncology to Participate in Upcoming Investor Conferences
Medium
Report
Olema Oncology to Participate in Upcoming Investor Conferences
2/3
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/31
07:03 pm
olma
Olema CFO Exit Puts Focus On Palazestrant Plans And Cash Discipline [Yahoo! Finance]
Low
Report
Olema CFO Exit Puts Focus On Palazestrant Plans And Cash Discipline [Yahoo! Finance]
1/30
07:12 pm
olma
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) [Yahoo! Finance]
Low
Report
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) [Yahoo! Finance]
1/30
04:01 pm
olma
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Low
Report
Olema Oncology Announces Departure of Chief Operating and Financial Officer
1/13
08:56 pm
olma
JPM26: Roche's rejuvenation strategy for the oncology and haematology portfolio [Yahoo! Finance]
Medium
Report
JPM26: Roche's rejuvenation strategy for the oncology and haematology portfolio [Yahoo! Finance]
1/9
11:46 am
olma
Olema Insider Sells $8 Million in Shares After 300% Stock Surge [Yahoo! Finance]
Medium
Report
Olema Insider Sells $8 Million in Shares After 300% Stock Surge [Yahoo! Finance]
1/9
06:10 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
09:47 pm
olma
How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
Medium
Report
How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
1/7
10:11 am
olma
The banker, the brothers, the friends and their frauds [Investment Executive - News]
Medium
Report
The banker, the brothers, the friends and their frauds [Investment Executive - News]
1/7
08:02 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/7
02:01 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/5
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/5
07:00 am
olma
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
12/12
08:06 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a "buy" rating on the stock.
12/11
01:19 pm
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an "outperform" rating on the stock.
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an "outperform" rating on the stock.
12/11
12:31 pm
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a "buy" rating on the stock.
12/11
10:38 am
olma
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT [Yahoo! Finance]
Medium
Report
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT [Yahoo! Finance]
12/11
08:07 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a "buy" rating on the stock.
12/10
09:08 am
olma
Roche boosts Olema after additional late-stage trial data for breast cancer drug [Seeking Alpha]
Medium
Report
Roche boosts Olema after additional late-stage trial data for breast cancer drug [Seeking Alpha]